BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21081655)

  • 21. Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.
    Anderson TM; Hess SD; Egilmez NK; Nwogu CE; Lenox JM; Bankert RB
    J Cancer Res Clin Oncol; 2003 Oct; 129(10):565-8. PubMed ID: 12923636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.
    Cutz JC; Guan J; Bayani J; Yoshimoto M; Xue H; Sutcliffe M; English J; Flint J; LeRiche J; Yee J; Squire JA; Gout PW; Lam S; Wang YZ
    Clin Cancer Res; 2006 Jul; 12(13):4043-54. PubMed ID: 16818704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
    Merk J; Rolff J; Becker M; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.
    Kowalczuk O; Kozlowski M; Milewski R; Minarowski L; Reszec J
    Adv Med Sci; 2015 Sep; 60(2):277-86. PubMed ID: 26118982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
    Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
    Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
    J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
    Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
    Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
    Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways.
    Tabbò F; Guerrera F; van den Berg A; Gaudiano M; Maletta F; Bessone L; Nottegar A; Costardi L; de Wijn R; Ruijtenbeek R; Delsedime L; Sapino A; Ruffini E; Hilhorst R; Inghirami G
    Eur J Cancer; 2021 Feb; 144():17-30. PubMed ID: 33316635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
    Chouaid C; Dujon C; Do P; Monnet I; Madroszyk A; Le Caer H; Auliac JB; Berard H; Thomas P; Lena H; Robinet G; Baize N; Bizieux-Thaminy A; Fraboulet G; Locher C; Le Treut J; Hominal S; Vergnenegre A
    Lung Cancer; 2014 Nov; 86(2):170-3. PubMed ID: 25214431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.
    Weiss GJ; Ganeshan B; Miles KA; Campbell DH; Cheung PY; Frank S; Korn RL
    PLoS One; 2014; 9(7):e100244. PubMed ID: 24987838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
    Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
    Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
    Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
    Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.